Abstract
For targeted radionuclide therapy to succeed as a single modality treatment, schemes must be devised which will enable the deposition in malignant cells of sterilising doses of radiation. Until such methods have been perfected, it is necessary to combine targeted radiotherapy in a rational manner with conventional anti-cancer treatments. Several means of delivery of therapeutic radionuclides are being evaluated but none of these yet appears to be as powerful as the simplest and most effective example, viz sodium ( 131 I)iodide treatment of disseminated thyroid carcinoma. The radiopharmaceutical ( 131 I)meta-iodobenzylguanidine ( 131 I MIBG) is an effective single agent for the treatment of neuroblastoma. However, uptake of the drug in malignant sites is heterogeneous, suggesting that this therapy alone is unlikely to cure disease. A growing body of experimental evidence indicates exciting possibilities for the integration of gene transfer with radionuclide targeting. This review covers aspects of the combination of gene manipulation and targeted radiotherapy, emphasising the potential of gene transfer to facilitate tumour targeting with low molecular weight radiopharmaceuticals.
Keywords: Gene Transfer, Targeted Radiotherapy, Neuroblastoma, Cytotoxic radionuclides, Antigen Gene Expression, Antibody Targeting, Carcinoembryonic antigen, Radiolabelled, Tumours, Anti mouse immunoglobulin responses, Receptor gene expression, Peptide Targeting, Sodium iodide symporter gene transfection, Tumour cells, Noradrenaline transporter, UVW NIS, UVW GFP, Untransfected UVW spheroids, Mosaic spheroid, NAT transfectants, GFP transfected, MIBG interactions, Sequencing, Radiological bystander effect
Current Pharmaceutical Design
Title: Applications of Gene Transfer to Targeted Radiotherapy
Volume: 6 Issue: 14
Author(s): R. J. Mairs, S. H. Cunningham, M. Boyd and S. Carlin
Affiliation:
Keywords: Gene Transfer, Targeted Radiotherapy, Neuroblastoma, Cytotoxic radionuclides, Antigen Gene Expression, Antibody Targeting, Carcinoembryonic antigen, Radiolabelled, Tumours, Anti mouse immunoglobulin responses, Receptor gene expression, Peptide Targeting, Sodium iodide symporter gene transfection, Tumour cells, Noradrenaline transporter, UVW NIS, UVW GFP, Untransfected UVW spheroids, Mosaic spheroid, NAT transfectants, GFP transfected, MIBG interactions, Sequencing, Radiological bystander effect
Abstract: For targeted radionuclide therapy to succeed as a single modality treatment, schemes must be devised which will enable the deposition in malignant cells of sterilising doses of radiation. Until such methods have been perfected, it is necessary to combine targeted radiotherapy in a rational manner with conventional anti-cancer treatments. Several means of delivery of therapeutic radionuclides are being evaluated but none of these yet appears to be as powerful as the simplest and most effective example, viz sodium ( 131 I)iodide treatment of disseminated thyroid carcinoma. The radiopharmaceutical ( 131 I)meta-iodobenzylguanidine ( 131 I MIBG) is an effective single agent for the treatment of neuroblastoma. However, uptake of the drug in malignant sites is heterogeneous, suggesting that this therapy alone is unlikely to cure disease. A growing body of experimental evidence indicates exciting possibilities for the integration of gene transfer with radionuclide targeting. This review covers aspects of the combination of gene manipulation and targeted radiotherapy, emphasising the potential of gene transfer to facilitate tumour targeting with low molecular weight radiopharmaceuticals.
Export Options
About this article
Cite this article as:
Mairs J. R., Cunningham H. S., Boyd M. and Carlin S., Applications of Gene Transfer to Targeted Radiotherapy, Current Pharmaceutical Design 2000; 6 (14) . https://dx.doi.org/10.2174/1381612003399194
DOI https://dx.doi.org/10.2174/1381612003399194 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitophagy in Neurodegeneration: An Opportunity for Therapy?
Current Drug Targets Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure- Activity Relationships of a Neuroprotective Peptide
Current Medicinal Chemistry NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates
Anti-Cancer Agents in Medicinal Chemistry The Importance of Melatonin and Mitochondria Interaction in Mood Disorders and Schizophrenia: A Current Assessment
Current Medicinal Chemistry Gene Transfer with Sequence-Defined Oligo(ethanamino)amides Bioreducibly Attached to a Propylenimine Dendrimer Core
Pharmaceutical Nanotechnology Organometallic Complexes: New Tools for Chemotherapy
Current Medicinal Chemistry Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Targeting Focal Adhesion Kinase in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry RANKL/RANK/OPG: Key Therapeutic Target in Bone Oncology
Current Drug Discovery Technologies Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Mechanisms of Prion Protein Aggregation
Protein & Peptide Letters Characterization of Cancer Stem Cells and Primary Cilia in Medulloblastoma
CNS & Neurological Disorders - Drug Targets Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies A Role for Calcineurin in Alzheimers Disease
Current Neuropharmacology Transcriptional Regulation of the p53 Tumor Suppressor Gene: A Potential Target for Cancer Therapeutics?
Recent Patents on DNA & Gene Sequences Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets NO Chimeras as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Pharmacological Activation of LXRs Decreases Amyloid-β Levels in Niemann-Pick Type C Model Cells
Current Pharmaceutical Biotechnology Selection and Characterization of Human Anti-MAGE-A1 scFv and Immunotoxin
Anti-Cancer Agents in Medicinal Chemistry Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry